3945-78-6

Usage

Classification

Synthetic nitrofuran derivative
A chemical compound obtained through synthetic processes, derived from nitrofuran

Properties

Antimicrobial and antiprotozoal
Exhibits activity against microorganisms and protozoa, helping to eliminate or inhibit their growth

Usage

Antiprotozoal agent
Commonly used to treat gastrointestinal infections caused by protozoa

Mechanism of action

Disrupts DNA replication in microorganisms
Inhibits the growth and multiplication of microorganisms by interfering with their DNA replication process

Effectiveness

Effective against a wide range of bacteria and protozoa
A valuable option for treating various infectious diseases due to its broad-spectrum activity

Tolerability

Generally well-tolerated with a low risk of adverse effects
Most users do not experience significant side effects, making it a safe option for treatment

InChI:InChI=1/C11H7N3O3/c15-14(16)10-6-5-9(17-10)11-12-7-3-1-2-4-8(7)13-11/h1-6H,(H,12,13)

Upstream product

• 25084-14-4 5-nitrofuran-2-carboxylic chloride 
• 95-54-5 1,2-diamino-benzene 
• 698-63-5 5-nitrofurane-2-carboxaldehyde 
• 18249-68-8 2-(5'-Brom-2'-furyl)benzimidazol 
• 4303-18-8 2-(5-chlorofuran-2-yl)-1H-benzo[d]imidazole 

Relevant academic research and scientific papers

Ruthenium(II)-catalyzed synthesis of 2-arylbenzimidazole and 2-arylbenzothiazole in water

Benzimidazoles/benzothiazoles are heterocyclic compounds which contain a five membered heteroatom and a benzene ring. They constitute a crucial structural unit of numerous bioactive compounds and natural products. Since the compounds containing benzimidaz

Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors

Matrix metalloproteinases (MMPs) are a large family of zinc-dependent endoproteases known to exert multiple regulatory roles in tumor progression and invasiveness. This encouraged over the years the approach of MMP, and particularly MMP-2, targeting for anticancer treatment. Early generations of MMP inhibitors, based on aspecific zinc binding groups (ZBGs) assembled on (pseudo)peptide scaffolds, have been discontinued due to the clinical emergence of toxicity and further drawbacks, giving the way to inhibitors with alternative zinc-chelator moieties or not binding the catalytic zinc ion. In the present paper, we continue the search for new non-zinc binding MMP-2 inhibitors: exploiting previously identified compounds, a virtual screening (VS) campaign was carried out and led to the identification of a new class of ligands. The structure-activity relationship (SAR) of the benzimidazole scaffold was explored by synthesis of several analogues whose inhibition activity was tested with enzyme inhibition assays. By performing the molecular simplification approach, we disclosed different sets of single-digit micromolar inhibitors of MMP-2, with up to a ten-fold increase in inhibitory activity and ameliorated selectivity towards off-target MMP-8, compared to selected lead compound. Molecular dynamics calculations conducted on complexes of MMP-2 with docked privileged structures confirmed that analyzed inhibitors avoid targeting the zinc ion and dip inside the S1′ pocket. Present results provide a further enrichment of our insights for the design of novel MMP-2 selective inhibitors.

ANTI-BACTERIAL AGENTS FROM BENZO[D]HETEROCYCLIC SCAFFOLDS FOR PREVENTION AND TREATMENT OF MULTIDRUG RESISTANT BACTERIA

Embodiments herein provide compounds and methods of making and using such compounds for prevention and treatment of multidrug resistant bacteria. In particular, embodiments are directed to anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria.

Chemistry of 2-substituted benzimidazoles. 1. 5-Amino-2-methyl(aryl, arylalkyl, pyridyl)benzimidazoles

A series of 2-substituted benzimidazoles was synthesized. These products were consecutively converted into 5-nitro- and 5-amino-2-substituted benzimidazoles.